Sagimet Biosciences Inc. Series A Common Stock (SGMT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $728.71M
Last updated: Nov 17, 2026 at 4:18 PM ET
Sagimet Biosciences Inc. Series A Common Stock (SGMT) Statistics
Sagimet Biosciences Inc. Series A Common Stock (SGMT) has a market cap of $728.71M and an enterprise value of $617.75M. Its share count is up 92.02% from a year earlier. It holds $110.96M more cash than debt, 15.23% of its market cap.
Total Valuation
Enterprise value is 15.23% below the market cap, as cash exceeds debt.
| Market Cap | $728.71M |
|---|---|
| Enterprise Value | $617.75M |
| Latest price (Nov 17, 2026) | $9.85 |
Key Dates
| Last Earnings Date | Nov 12, 2026 |
|---|---|
| Fiscal Year End | December |
Price Statistics
The stock is up 27.10% over 52 weeks and trades at its 50-day average.
| Beta (1Y) | 1.88 |
|---|---|
| 52-Week Change | +27.10% |
| 1-Month Change | +11.17% |
| 3-Month Change | -6.90% |
| 6-Month Change | +50.61% |
| Total Return (1Y) | +27.10% |
| Total Return (3Y CAGR) | +49.28% |
| Return vs SPY (1Y) | +14.40% |
| Max Drawdown (1Y) | -42.04% |
| Max Drawdown (3Y) | -89.69% |
| Sharpe Ratio (1Y) | 0.29 |
| Correlation with SPY (1Y) | 0.33 |
| 50-Day Average | $9.85 |
| 200-Day Average | $7.75 |
| 52-Week Range | $4.50 to $11.45 |
| RSI (14 Days) | 48.6 |
| Average Volume (20 Days) | 1.04M |
Financial Position
Current assets cover 6.34x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.34x |
|---|---|
| Quick Ratio | 6.34x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -22.02% and return on assets is -18.90% over the last 12 months.
| Return on Equity (ROE) | -22.02% |
|---|---|
| Return on Assets (ROA) | -18.90% |
| ROA (5Y Average) | -46.96% |
Scores
SGMT has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Operating Income | -$59.86M |
| Pretax Income | -$53.32M |
| Net Income | -$53.32M |
| Reported EPS (TTM) | -$1.19 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 85.85% of the $282.09M in total assets.
| Cash and Equivalents | $110.96M |
|---|---|
| Total Debt | $0 |
| Net Cash | $110.96M |
| Net Cash Per Share | $1.78 |
| Working Capital | $202.74M |
| Shareholder Equity | $242.18M |
| Book Value Per Share | $3.88 |
| Total Assets | $282.09M |
| Total Liabilities | $39.91M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$43.66M |
|---|---|
| FCF Per Share | -$0.62 |
| Depreciation and Amortization | $754.00K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -17.05% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -17.05% |
Dividends and Yields
SGMT does not pay a dividend.
| Buyback Yield | -28.50% |
|---|---|
| Shareholder Yield | -28.50% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SGMT
What is SGMT's market cap?
Sagimet Biosciences Inc. Series A Common Stock has a market cap of $728.71M. Its enterprise value, which adds debt and subtracts cash, is $617.75M.
How many shares of SGMT are outstanding?
Sagimet Biosciences Inc. Series A Common Stock has 62.34M shares outstanding. The count is up 92.02% from a year earlier.
Does SGMT pay a dividend?
No. Sagimet Biosciences Inc. Series A Common Stock does not pay a dividend.
How much debt does SGMT have?
Sagimet Biosciences Inc. Series A Common Stock has $0 of total debt and $110.96M of cash and equivalents, a net cash position of $110.96M.
SGMT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors